To treat inflammatory diseases, including rheumatoid arthritis and Crohn’s disease, biopharmaceutical drugs targeting TNF, IL-1, and IL-6 provided satisfactory outcomes [34,35]. The gene discussed is TNF; the disease is rheumatoid arthritis.